Gallium-68 Prostate-Specific-Membrane-Antigen-11 (Ga-68 PSMA-11) was the first prostate-specific PET agent approved by the FDA for evaluating prostate cancer recurrence and metastatic disease. Here, FOLH1 is linked to prostate carcinoma.